

Central Nervous System Neoplasms

[View the current Central Nervous System Neoplasms InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Central_Nervous_System_Neoplasms.html) ([PDF](#))
(http://www.bioportfolio.com/indepth/Central_Nervous_System_Neoplasms.html) - Regularly Updated.

Recent Publications on Central Nervous System Neoplasms:



- [Progress in primary CNS lymphoma.](#)
*A 40-year-old man with relapsing-remitting multiple sclerosis (MS)...*13th November, 2009
Department of Radiation Oncology, Calvary Mater Newcastle, NSW 2310,- Lancet. 2009 Oct 31;374(9700):1477-8. Epub 2009 Sep 18. ([DOI Direct Link](#))
- [High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.](#)
*BACKGROUND: Chemotherapy with high-dose methotrexate is the conventional...*13th November, 2009
Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan,- Lancet. 2009 Oct 31;374(9700):1512-20. Epub 2009 Sep 18. ([DOI Direct Link](#))
- [CCM2 and CCM3 proteins contribute to vasculogenesis and angiogenesis in human placenta.](#)
*Placenta as an ideal model to study angiogenic mechanisms have been...*5th November, 2009
Department of Histology and Embryology, Akdeniz University, School of- Histol Histopathol. 2009 Oct;24(10):1287-94.
- [Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.](#)
*A multiplex ligation-dependent probe amplification assay for simultaneous...*30th October, 2009
- Ann Neurol. 2009 Sep;66(3):259-61. ([DOI Direct Link](#))
- [Another complication of natalizumab treatment? Taking the challenge.](#)
*A multiplex ligation-dependent probe amplification assay for simultaneous...*30th October, 2009
- Ann Neurol. 2009 Sep;66(3):264-6. ([DOI Direct Link](#))
- [Natalizumab and central nervous system lymphoma: no clear association.](#)
*A multiplex ligation-dependent probe amplification assay for simultaneous...*30th October, 2009
- Ann Neurol. 2009 Sep;66(3):261-2. ([DOI Direct Link](#))
- [Natalizumab: a double-edged sword?](#)
*A multiplex ligation-dependent probe amplification assay for simultaneous...*30th October, 2009
- Ann Neurol. 2009 Sep;66(3):262-3. ([DOI Direct Link](#))
- [Primary central nervous system lymphoma in a patient treated with natalizumab.](#)
*A 40-year-old man with relapsing-remitting multiple sclerosis (MS)...*30th October, 2009
Department of Neurology, Klinikum rechts der Isar, Technische Universitat- Ann Neurol. 2009 Sep;66(3):403-6. ([DOI Direct Link](#))
- [Pigmented lesions of the central nervous system: radiologic-pathologic correlation.](#)
*Pigmented lesions of the central nervous system (CNS) are a diverse group...*16th October, 2009

Department of Radiologic Pathology, Armed Forces Institute of Pathology, - Radiographics. 2009 Sep-Oct;29(5):1503-24. ([DOI Direct Link](#))

- [Statistical and trial design considerations in central nervous system prophylaxis studies.](#)
*The prognosis is very poor for patients with cancer who develop central...*9th October, 2009
Geron- Semin Oncol. 2009 Aug;36(4 Suppl 2):S69-76. ([DOI Direct Link](#))
- [Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.](#)
*Three methods are routinely used to diagnose neoplastic meningitis (NM)...*9th October, 2009
Department of Neurology and Neurological Surgery, Division of- Semin Oncol. 2009 Aug;36(4 Suppl 2):S35-45. ([DOI Direct Link](#))
- [Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.](#)
*Central nervous system (CNS) involvement is a serious complication of...*9th October, 2009
Division of Clinical Neuro-oncology, Department of Neurology, University- Semin Oncol. 2009 Aug;36(4 Suppl 2):S25-34. ([DOI Direct Link](#))
- [Central nervous system disease in hematologic malignancies: historical perspective and practical applications.](#)
*Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching...*9th October, 2009
St. Jude's Children's Research Hospital, Memphis, TN 38105, USA.- Semin Oncol. 2009 Aug;36(4 Suppl 2):S2-S16. ([DOI Direct Link](#))
- [The science of prevention: novel strategies for and new insights into central nervous system prophylaxis in patients with cancer.](#)
*Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching...*9th October, 2009
Penn State Hershey Medical Center, Hershey, PA, USA.- Semin Oncol. 2009 Aug;36(4 Suppl 2):S1. ([DOI Direct Link](#))
- [\[Neuropathology and molecular pathology of gliomas\]](#)
*Gliomas are the most frequent primary brain tumours. The WHO...*30th September, 2009
Unite de neuropathologie, Institut universitaire de pathologie CHUV, - Rev Med Suisse. 2009 Jul 15;5(211):1501-4.

Central Nervous System Neoplasms Clinical Trials:



- [Stem Cell Transplant for High Risk Central Nervous System \(CNS\) Tumors](#)

Central Nervous System Neoplasms Patents:



- 6951924- [Antibodies against secreted protein HTEBYII](#)

- 7169901- [Anti-VEGF antibodies](#)
- 7175988- [Human G-protein Chemokine Receptor \(CCR5\) HDGNR10](#)
- 7176304- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7189690- [Albumin fusion proteins](#)
- 7196164- [Secreted protein HHTLF25](#)
- 7205139- [Tissue plasminogen activator-like protease](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7235529- [Brain-associated inhibitor of tissue-type plasminogen activator](#)
- 7238660- [Albumin fusion proteins](#)
- 7238667- [Albumin fusion proteins](#)
- 7163797- [50 human secreted proteins](#)
- 7141547- [Albumin fusion proteins comprising GLP-1 polypeptides](#)
- 7091315- [Protein HDPBQ71](#)
- 6978166- [System for use in displaying images of a body part](#)
- 6986890- [Anti-human VEGF receptor Flt-1 monoclonal antibody](#)
- 6994857- [Albumin fusion proteins](#)
- 7026447- [53 human secreted proteins](#)
- 7034009- [Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor \(VEGF-R\)](#)
- 7041803- [Galectin 11](#)
- 7052693- [Anti-human VEGF receptor FLT-1 monoclonal antibody](#)
- 7060269- [Anti-VEGF antibodies](#)
- 7072704- [System for indicating the position of a surgical probe within a head on an image of the head](#)
- 7078186- [Apoptosis related polynucleotides, polypeptides, and antibodies](#)
- 7365166- [Anti-VEGF antibodies](#)
- 7368527- [HADDE71 polypeptides](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7514207- [Methods of screening for compounds that decrease phosphorylation of merlin and may be useful in cancer treatment](#)
- 7514252- [Cell-specific and/or tumor-specific promoter retargeting of herpes .gamma. 34.5 gene expression](#)
- 7517864- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7521424- [Albumin fusion proteins](#)
- 7541160- [ELISA for VEGF](#)
- 7569384- [Albumin fusion proteins](#)
- 7592010- [Albumin fusion proteins](#)
- 7615214- [Anti-human VEGF receptor Flt-1 monoclonal antibody](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7498414- [Human antibodies specific to KDR and uses thereof](#)
- 7494977- [Polypeptides homologous to VEGF and BMP1](#)
- 7368531- [Human secreted proteins](#)
- 7371377- [Antibodies to polypeptides homologous to VEGF and BMP1](#)
- 7375193- [Anti-VEGF antibodies](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7390637- [Keratinocyte derived interferon](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7446176- [12 human secreted proteins](#)
- 7459531- [50 Human secreted proteins](#)
- 7482013- [Albumin fusion proteins](#)

- 7615215- [Anti-human VEGF receptor Flt-1 monoclonal antibody](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

